A fundamental way to circumvent the limited number of actionable oncogenic-driving events is to identify molecular targets that become essential in a specific tumor’s genetic landscape. Understanding the network of genetic interactions such as Synthetic Lethality (SL) and Synthetic Rescue (SR) uncovers such potential targets. Identifying these interactions via large-scale functional genomic screens offers promising new opportunities for selective therapies in cancer, drawing a lot of attention to SL in recent years. However, the majority of SL interactions identified in lab screens do not have translational significance. Addressing this challenge, we developed a data-driven approach that mines big cancer data to identify clinically significant interactions. Our approach can significantly increase the number of patients that benefit from precision oncology treatments. This state-of-the-art computational multi-omics enables us to (1) recommend the most effective drugs to combat tumors of individual patients; (2) to stratify the most relevant patients for a given treatment; and (3) to facilitate the development of new drugs by identifying promising new drug targets.
Prof. Eytan Ruppin is the Director of the Cancer Data Science Laboratory at the National Cancer Institute (NCI) in Bethesda, MD USA. Prof. Ruppin is a computational biologist whose research is focused on developing and harnessing multi-omics data to better understand the pathogenesis of cancer, its evolution and treatment. Areas of Expertise: big data analysis, machine learning, bioinformatics and computational biology, genetic interactions in cancer and immunotherapy.
Prof. Ze’ev Ronai is theDirector of the Prebys NCI-designated Cancer Center at Sanford-Burnham Medical Discovery Institute in La Jolla, CA, whose research is focused on rewired signal transduction pathways that can be used for cancer therapy. Area of expertise: Melanoma, protein homeostasis and targeted therapy. Prof. Ronai’s interest in precision medicine dates back to 1991, when he established a highly sensitive PCR approach to detect low incidence mutant oncogenes.
Prof. Eyal Gottlieb is the Director of the Rappaport Technion Integrated Cancer Center, Israel, and formerly the Director of the Cancer Metabolism Research Unit at the Cancer Research UK Beatson Institute in Glasgow, UK. Areas of Expertise: cancer metabolism, metabolomics, drug development and precision medicine in oncology.
Tuvik is an experienced entrepreneur, executive and technical leader, who has spent the last 20 years building and leading companies in the healthcare, financial and aerospace domains. In his diverse career he served in both technical and executive roles, often combining the two. He is a co-founder of MedAware Ltd., a leader in patient safety solutions, and serves as its Executive Chairman. Tuvik holds a B.Sc. in Mathematics from Tel Aviv University and a PhD in Computational Neuroscience from the Hebrew University.
Formerly the Chairman of the Obstetrics Gynecology and Infertility Division in Sheba Medical Center, Tel Aviv University Israel. Eyal has extensive experience in managing medical organizations with large scale teams, and as a director and investor in innovative start-up companies in the computational biotech and pharma fields.
Emmanuel brings with him more than 20 years of experience in the Biotech start up ecosystem. He held several senior positions, among others as executive VP and COO of VBL Therapeutics (Nasdaq: VBLT) where he led the Business Development and Strategy Department including worldwide BD campaigns. Emmanuel holds a Pharm D from Paris University and an MBA from Northwestern , Chicago IL.